Council researchers have developed a long-acting contraceptive vaginal system approved by the FDA that can prevent pregnancy for one full year.
Twenty years of research and development led to the US FDA approval of Annovera™ (segesterone acetate and ethinyl estradiol vaginal system), the first contraceptive to provide a full year of pregnancy protection while fully under the control of a woman. Annovera should be available to women in the United States by early 2020.
A soft, reusable flexible silicone ring, Annovera can be inserted and removed by a woman herself. Left in place for 21 days and removed for seven days each cycle, it does not require refrigeration.
The first in a new class of contraceptives.
Developed at the fraction of a cost of pharmaceutical development, important public and private donors from around the world supported the research and development of Annovera. These include the United States Agency for International Development (USAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), the Bill & Melinda Gates Foundation, the Avis and Clifford Barrus Medical Foundation, the World Health Organization (WHO), and critical support from individuals to the Population Council.